Sarciron M E, Lawton P, Saccharin C, Petavy A F, Peyron F
Department of Parasitology and Medical Mycology, Claude Bernard University, Lyon, France.
Antimicrob Agents Chemother. 1997 Jul;41(7):1531-6. doi: 10.1128/AAC.41.7.1531.
The activity against Toxoplasma gondii of 2',3' dideoxyinosine (ddI), an anti-human immunodeficiency virus drug, was examined in an in vitro and in vivo study. Cell cultures infected with a strain known to cause chronic infections were used to show the dose-dependent effect of this drug compared with spiramycin and sulfadiazine. When a dose of 4 microg/ml was used, no infected THP-1 cells or parasites were found after 60 h of incubation. An electron-microscopic study confirmed that after 12 h at 1 microg/ml, the few parasites observed were severely altered. The treatment of chronically infected mice 3 months postinfection showed that a 30-day treatment with 2 mg of ddI/ml induced a significant reduction in the number of T. gondii cysts in the cerebral tissue. These cysts were not viable, as confirmed by immunofluorescence and reinfection experiments. These experiments suggest a possible role for ddI in the treatment of toxoplasmosis, and this possibility deserves further investigation.
在一项体外和体内研究中，对一种抗人类免疫缺陷病毒药物2',3'-双脱氧肌苷（ddI）抗刚地弓形虫的活性进行了检测。使用感染了已知会引起慢性感染的菌株的细胞培养物，以显示该药物与螺旋霉素和磺胺嘧啶相比的剂量依赖性效应。当使用4微克/毫升的剂量时，孵育60小时后未发现受感染的THP-1细胞或寄生虫。电子显微镜研究证实，在1微克/毫升的浓度下作用12小时后，观察到的少数寄生虫发生了严重改变。对感染3个月后的慢性感染小鼠进行治疗表明，用2毫克/毫升的ddI进行30天治疗可使脑组织中刚地弓形虫囊肿的数量显著减少。通过免疫荧光和再感染实验证实，这些囊肿没有活力。这些实验表明ddI在弓形虫病治疗中可能发挥作用，这种可能性值得进一步研究。
